Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · May 18, 2024

SGLT2 Inhibitors and the Risk for Dialysis and CVD in Patients With Stage 5 CKD

Annals of Internal Medicine


Additional Info

Annals of Internal Medicine
Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease
Ann. Intern. Med 2024 Apr 30;[EPub Ahead of Print], FS Yen, CM Hwu, JS Liu, YL Wu, K Chong, CC Hsu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading